HGH Fragment 176-191

Overview

HGH Fragment 176-191 is a synthetic peptide modeled on the C-terminal region (residues 176-191) of human growth hormone. It was designed to isolate the lipolytic and adipocyte-active portion of GH while removing the regions associated with IGF-1 stimulation and growth-promoting effects.

Research Background

Fragment 176-191 has been studied in research on lipolysis, adipocyte biology, and metabolic regulation. It is examined as a tool for separating GH’s effects on fat metabolism from its broader anabolic and growth-promoting actions.

Storage & Handling

Store lyophilized peptide at -20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2–8°C and use within recommended timeframes. Handle under sterile laboratory conditions and avoid repeated freeze-thaw cycles.

Disclaimer:
This product is for laboratory research use only. It is not intended for human or animal consumption or for use in any diagnostic, therapeutic, or clinical applications.

Fragment 176-191 acts on adipocytes to stimulate lipolysis (breakdown of triglycerides) and inhibit lipogenesis (formation of new fat). The mechanism appears to involve beta-3 adrenergic-like signaling and modulation of adipocyte metabolism, but importantly, the fragment does not bind the GH receptor and does not raise IGF-1, distinguishing it pharmacologically from full-length GH.

Fragment 176-191 is studied in research on adipose tissue metabolism, lipolysis, and energy balance. It is of interest to investigators studying GH-related fat metabolism in isolation from the somatotropic axis.